Publications by authors named "Shukui Qin"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,386

Total Likes

392

Extended Reach

1,105,027

Social Features

195
A
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, Masafumi Ikeda, Peter R Galle, Michel Ducreux, Tae-You Kim, Masatoshi Kudo, Valeriy Breder, Philippe Merle, Ahmed O Kaseb

May 2020

Videos about Article: user user

2 3 193 10 122

View All Article and Social Media Activity
C
China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).
Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Shukui Qin

Liver Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
Maeve A Lowery, Lucjan S Wyrwicz, Do-Youn Oh, Kai-Keen Shiu, Patricio Yañez, Shukui Qin

Eur J Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study.
Shukui Qin, Shanzhi Gu, Stephen L Chan, Yuxian Bai, Zhenggang Ren

Lancet Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chinese expert consensus on diagnosis and treatment of small gastrointestinal stromal tumors (2025 edition).
Zhidong Gao, Chao Wang, Jian Li, Peng Zhang, Xin Wu, Shukui Qin

Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka

J Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy.
Leqian Ying, Yini Zhu, Lu Zhang, Min Ji, Meidan Wang, Shukui Qin

Cell Death Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Qingxia Fan

Eur J Med Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
Arvind Dasari, Cathy Eng, Sara Lonardi, Rocio Garcia-Carbonero, Toshiki Masuishi, Shukui Qin

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics evaluation of oroxylin A in Chinese healthy volunteers: a phase I, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect study.
Fan Yang, Xianmin Meng, Shukui Qin, Qinglong Guo, Libin Wei

Clin Transl Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.
Yi Wang, Yifu He, Zhiqiang Wang, Haijun Zhong, Zuoxing Niu, Shukui Qin

Ther Adv Med Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study.
Ningning Zhang, Tian Liu, Ming Luo, Jihui Hao, Shukui Qin

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
Kohei Shitara, Sylvie Lorenzen, Jin Li, Yuxian Bai, Manuel González Fernández, Shu-Kui Qin

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study.
Yoon Jun Kim, Philippe Merle, Richard S Finn, Masatoshi Kudo, Heinz-Josef Klümpen, Shukui Qin

Liver Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).
Jianming Xu, Lin Shen, Jie Li, Zhiwei Zhou, Chunmei Bai, Shukui Qin

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second-line pembrolizumab for advanced HCC: Meta-analysis of the phase III KEYNOTE-240 and KEYNOTE-394 studies.
Richard S Finn, Kangsheng Gu, Xi Chen, Philippe Merle, Kyung-Hun Lee, Shukui Qin

JHEP Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin

Lancet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study.
Shukui Qin, Yuxian Bai, Jin Li, Hongming Pan, Suxia Luo

Adv Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mecapegfilgrastim prophylaxis for neutropenia in patients with non-myeloid malignancies: A Chinese nationwide real-world study.
Shukui Qin, Yanxia Shi, Peifen Fu, Nong Xu, Chenyu Mao, Yongqing Li

BMC Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren

Lancet· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024.
George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin

Hepatol Int· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study.
Gang Cheng, Yong Chen, Nong Xu, Chenyu Mao, Ningling Zhang, Shukui Qin

Transl Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial - Author's reply.
Shukui Qin

Lancet· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tislelizumab versus Sorafenib in First-Line Treatment of Unresectable Hepatocellular Carcinoma: Impact on Health-Related Quality of Life in RATIONALE-301 Study.
Richard S Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Shukui Qin

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT.
Richard S Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J Knox

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
Jiujie Cui, Shukui Qin, Yuhong Zhou, Shuang Zhang, Xiaofeng Sun

Signal Transduct Target Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis